已收盘 09-12 16:00:00 美东时间
-0.040
-2.56%
<p>Jupiter Neurosciences, Inc. announced the launch of its Nugevia™ e-commerce platform and pre-orders for three nutraceutical supplements targeting longevity and wellness. The products, enhanced with the company’s JOTROL™ resveratrol delivery platform, offer improved bioavailability and are designed to support skin health, energy, and cognitive function. The launch supports Jupiter’s dual-path strategy, combining CNS therapeutic development with...
08-26 12:00
Jupiter Neurosciences, Inc. announced that NBA Hall of Fame Chris Webber has joined as the brand ambassador for its new longevity supplement line, Nugevia™. Webber, known for his championship mindset and dedication to peak performance, aligns with Nugevia’s mission to support longevity, resilience, and elite performance backed by clinical science. Nugevia™, powered by Jupiter’s patented JOTROL™ technology, offers enhanced bioavailability and is d...
08-19 12:12
Jupiter Neurosciences, Inc. ( ($JUNS) ) has released a notification of late fil...
08-15 06:23
MND combines proprietary resveratrol-based platform and NovaSOL® Curcumin to enhance cognitive performance and support neuroprotective healthJupiter, Florida, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences,
08-11 20:12
Jupiter Neurosciences introduces Nugevia MND, a supplement combining JOTROL™ resveratrol and NovaSOL® Curcumin to enhance cognitive performance and support neuroprotective health. The product targets aging adults and aims to capitalize on the growing longevity market. Key benefits include improved memory, reduced inflammation, and protection against cognitive decline.
08-11 12:00
JOTROL™ is currently advancing toward a Phase IIa trial in Parkinson's Disease, following breakthrough preclinical data in a well-established MPTP mouse model that demonstrated meaningful improvements in motor
07-23 20:14
Jupiter Neurosciences开发的JOTROL™是一种专利的高生物利用度白藜芦醇平台,解决了传统白藜芦醇生物利用度低和胃肠道副作用的问题。该平台已显示比普通白藜芦醇高9倍的生物利用度,且无副作用,可用于治疗帕金森病等中枢神经系统疾病。其消费者产品线Nugevia™预计于2025年第三季度推出,专注于认知健康和抗衰老领域。
07-23 12:00
Jupiter Neurosciences (NASDAQ: JUNS) has regained compliance with Nasdaq's continued listing standard for minimum share price under Rule 5550(a)(2). The Company's common stock maintained an average closing price of at least $1.00 over 13 consecutive days (June 18-July 8, 2025), resolving its non-compliance issue. This milestone was disclosed in a Form 8-K filed on July 10, 2025.
07-10 20:05
Jupiter Neurosciences, Inc. ( ($JUNS) ) just unveiled an update. On July 2, 202...
07-10 04:57
Jupiter Neurosciences, Inc., a clinical-stage pharmaceutical company, launched Nugevia™ PWR, a daily mitochondrial health supplement designed to support cellular energy, endurance, and recovery. PWR combines JOTROL™, a high-bioavailability resveratrol formulation, with NovaSOL® solubilized CoQ10 to enhance mitochondrial function and protect against oxidative stress. Targeting the growing longevity and wellness markets, PWR offers long-term benefi...
06-30 19:15